Yazar "Uysal, Ayşe" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience
    (2018) Uysal, Ayşe; Soyer, Nur Akad; Özkan, Melda; Şahin, Fahri; Vural, Filiz; Töbü, Mahmut; Saydam, Güray
    Background/aim: Carfilzomib (CFZ) is a new-generation proteasome inhibitor with significant activity in relapsed or refractory multiple myeloma (R/R-MM). We have retrospectively evaluated R/R-MM patients who were treated with CFZ plus dexamethasone. Materials and methods: Twenty-one R/R-MM patients who were treated with CFZ plus dexamethasone between October 2013 and January 2016 were screened. the patients were followed until March 2016 after CFZ treatment. Results: Ten (47.6%) of the patients were female and 11 (52.4%) of them were male. the median age was 62 (47–76) years. the median number of prior treatment lines was 3 (2–7). the median number of administered cycles of treatment for CFZ was 4 (1–10). the median overall response rate was 26.3%. the most common hematological adverse events were anemia and thrombocytopenia (38%). the most common nonhematological adverse event was fatigue (71.4%). One patient died because of a cerebrovascular event and 1 patient died because of pneumonia during the treatment period. the median duration of response rate and time to next therapy were 8 (7–9) and 3 (2–16) months, respectively. the median overall survival was 8 (0.5–33) months. Conclusion: Despite the small number of patients, our results suggest that CFZ provides acceptable responses in heavily pretreated R/R-MM patients.
  • Küçük Resim Yok
    Öğe
    Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience
    (2018) Soyer, Nur; Patır, Pusem; Uysal, Ayşe; Duran, Mustafa; Ünal, Hatice Demet; Onmuş, İsabel Raika Durusoy; Şahin, Fahri
    Background/aim: in Turkey, lenalidomide plus dexamethasone (RD) has been used to treat relapsed/refractory multiple myeloma (RRMM) since 2010. This retrospective, single-center study evaluated the efficacy and tolerability of RD in patients with RRMM between October 2010 and June 2016. Materials and methods: Patients’ records were reviewed, and overall (OS) and progression-free survival (PFS) were assessed. Results: One hundred and twenty patients (71 males; 59.2%) were included in the study. the median number of prior lines of treatment was one (1–4); 72 patients (60.0%) received RD as second-line therapy and 51 patients (42.5%) had previously undergone autologous stem cell transplantation (ASCT). the overall response rate was 72.5%, with 19% of these patients achieving a complete response. the median length of follow-up and duration of response to RD was 14 months and 19 months, respectively. Median OS and PFS were 32 and 21 months, respectively. Prior ASCT, an overall response, and treatment with RD for >12 cycles were identified as independent prognostic factors for OS and PFS. Adverse events (AEs) occurred in 69 (57.5%) and 14 patients (11.7%) discontinued treatment due to AEs. Conclusions: We found RD to be safe, well tolerated, and effective in RRMM in everyday clinical practice in Turkey.
  • Küçük Resim
    Öğe
    Hasat sonrası nar meyvelerinde Botrytis cinerea Pers.: Fr.’e karşı bazı fungisitlerin etkinliği üzerine araştırmalar
    (Ege Üniversitesi, 2011) Uysal, Ayşe; Kınay Teksür, Pervin
    Nar meyvelerinde taç çürüklüğüne neden olan Botrytis cinerea hasat sonrası ekonomik kayıplara neden olmaktadır. Hasat sonrası narlarda B. cinerea’ya karşı ruhsatlı bir fungisit bulunmamaktadır. Bu nedenle hasat sonrasında B. cinerea’nın kontrolünde etkili olabilecek fungisitlere gereksinim vardır. Çalışmada, en yoğun yetiştiriciliğin ve depolamanın yapıldığı Antalya ilinden; toplam 11, İzmir’den 2 soğuk hava deposundan toplanan infekteli nar meyvelerinden 33 B. cinerea izolatı elde edilmiştir. Bunlar içerisinden 27 izolatın miselyal gelişimine karşı 10 fungisitin etkiliği in vitro koşullarda ve daha sonra da meyve testleriyle araştırılmıştır. Elde edilen sonuçlara göre, in vitro koşullarda fludioxanil, cyprodinil+fludioxanil ve fenhexamid B. cinerea’nın miselyal gelişimin engellenmesinde yüksek, pyrimethanil, thiabendazole, imazalil ve boscalid+pyraclostrobin orta derecede etkili olurken, azoxystrobin ve boscalid düşük derecede etkili olmuştur. Meyve testlerinde ise, en etkili fungisit %78.58’lik oranla fludioxanil olmuş, bunu sırasıyla boscalid+pyraclostrobin (%64.29) ve pyrimethanil (%64.28) takip etmiştir. Cyprodinil+fludioxanil (%50), cyprodinil (%50.01) ve azoxystrobin (%42.86) orta derecede etkililik göstermiştir. Hasat sonrasında çok yaygın olarak kullanılan fungisitlerden imazalil ve TBZ ise B. cinerea çürüklüklerine karşı düşük etkililik göstermiştir. Bu sonuçlara göre, fludioxanil narlarda hasat sonrasında B. cinerea’nın kontrolünde en etkili fungisit olarak saptanmıştır.